Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does managed care fuel pharmaceutical industry growth?

M D Murray1, F W Deardorff

  • 1School of Pharmacy and Pharmaceutical Science, Purdue University, Indianapolis, Indiana, USA. murray_m@regenstrief.iupui.edu

Pharmacoeconomics
|May 27, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with exacerbation of heart failure include treatment adherence and health literacy skills.

Clinical pharmacology and therapeutics·2009
Same author

The use of propensity scores in pharmacoepidemiologic research.

Pharmacoepidemiology and drug safety·2008
Same author

Determining the effectiveness of torasemide and furosemide in heart failure: design of a randomised comparison using the regenstrief medical record system.

Clinical drug investigation·2008
Same author

Social support and health-related quality of life in chronic heart failure patients.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2002
Same author

Pharmaceutical care in chain pharmacies: beliefs and attitudes of pharmacists and patients.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2002
Same author

Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure.

The American journal of medicine·2001

Managed-care organizations and the pharmaceutical industry have conflicting goals regarding drug costs. Common ground exists in researching how innovative drugs impact overall patient healthcare expenses.

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Healthcare Management

Background:

  • Managed-care organizations (MCOs) aim to control drug spending, while the pharmaceutical industry seeks to expand sales of branded products.
  • The dynamic between MCOs and pharmaceutical companies involves strategic maneuvering to achieve opposing objectives.
  • Factors like increased insurance coverage for prescriptions and the availability of novel drugs currently favor the pharmaceutical industry.

Purpose of the Study:

  • To explore the divergent objectives of managed-care organizations and the pharmaceutical industry.
  • To identify potential common ground and collaborative opportunities between these entities.
  • To analyze the current market dynamics influencing the relationship between managed care and pharmaceutical sales.

Main Methods:

Related Experiment Videos

  • Analysis of the stated objectives and market strategies of managed-care organizations.
  • Review of the business models and growth drivers within the pharmaceutical industry.
  • Examination of healthcare payment trends and the impact of innovative drug products.
  • Assessment of existing marketing data and industry reports.

Main Results:

  • MCOs prioritize cost reduction or stabilization of drug expenses.
  • The pharmaceutical industry focuses on increasing sales of high-cost, branded medications.
  • Prescription cost shifts from out-of-pocket to insurer payments benefit pharmaceutical growth.
  • The availability of innovative drugs also supports pharmaceutical industry expansion.

Conclusions:

  • A potential area for collaboration lies in jointly investigating the total healthcare cost impact of innovative drugs.
  • Despite opposing immediate goals, shared interests may emerge through research on drug cost-effectiveness.
  • Current market dynamics show the pharmaceutical industry benefiting from managed-care structures, an outcome with ironic implications.